Advertisement

Topics

Social Media about Biotechnology, Pharmaceutical and Healthcare

11:41 EST 14th December 2018 | BioPortfolio

Read the latest opinions - blogs from pharmaceutical and life science industry experts.

Showing News Articles 1–25 of 45,000+

Friday 14th December 2018

Sliding into the weekend... #SnowBearspic.twitter.com/aKiOkpHgcA

Sliding into the weekend... #SnowBears pic.twitter.com/aKiOkpHgcA

Exclusive Q&A: AveXis President David Lennon talks gene therapy in 2019 $NVS $ONCE $BIIB $IONS $RHHBY $PTC http://ow.ly/Kh9D30mZkT0 

Exclusive Q&A: AveXis President David Lennon talks gene therapy in 2019 $NVS $ONCE $BIIB $IONS $RHHBY $P

Johnson & Johnson shares sharply drop at the open after Reuters reports that the company knew for decades about asbestos in baby powder talc supply http://cnbc.com/id/105622829 pic.twitter.com/GF3DSCFHOB

Johnson & Johnson shares sharply drop at the open after Reuters reports that the company knew for decades about asbestos in baby powder talc supply http://cnbc.com/id/105622829  pic.twitter.com/GF3DSCFHOB

Darlene Coker knew she was dying. She just wanted to know why. @specialreports investigates Johnson & Johnson’s decades-long history of carcinogenic asbestos showing up in its talc https://reut.rs/2EvsBdl pic.twitter.com/PhP71yFoMJ

Darlene Coker knew she was dying. She just wanted to know why. @specialreports investigates Johnson & Johnson’s decades-long history of carcinogenic asbestos showing up in its talc https://reut.rs/2EvsBdl  pic.twitter.com/PhP71yFoMJ

Novartis pulls EU filing for canakinumab for the prevention of major cardiovascular events https://www.firstwordpharma.com/node/1611626  $NVS

Novartis pulls EU filing for canakinumab for the prevention of major cardiovascular events https://www.firstwordpharma.com/node/1611626  $NVS

Amgen scraps deal with Advaxis to develop cancer immunotherapy ADXS-NEO https://www.firstwordpharma.com/node/1611622  $AMGN $ADXS

Amgen scraps deal with Advaxis to develop cancer immunotherapy ADXS-NEO https://www.firstwordpharma.com/node/1611622  $AMGN $ADXS

$NVS withdraws EMA application for canakinumab in CVD prevention https://www.ema.europa.eu/documents/medicine-qa/questions-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_en.pdf … Guess not that big a surprise

$NVS withdraws EMA application for canakinumab in CVD prevention https://www.ema.europa.eu/documents/medicine-qa/questions-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_en.pdf … Guess not that big a surprise after FDA CRL, but still hurts after you spent hundreds of millions on a 10,000-patient 4-Year trial https://www.ema.e

EMA concludes Omega-3 fatty acid medicines no longer considered effective in preventing heart disease https://www.ema.europa.eu/en/medicines/human/referrals/omega-3-fatty-acid-medicines … $AMRN REDUCE-IT data seem not included in the review though

EMA concludes Omega-3 fatty acid medicines no longer considered effective in preventing heart disease https://www.ema.europa.eu/en/medicines/human/referrals/omega-3-fatty-acid-medicines … $AMRN REDUCE-IT data seem not included in the review though

$PFE withdraws EMA application for #biosimilar Humira https://www.ema.europa.eu/documents/medicine-qa/questions-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_en.pdf … Another retreat by a big player in a highly competitiv

$PFE withdraws EMA application for #biosimilar Humira https://www.ema.europa.eu/documents/medicine-qa/questions-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_en.pdf … Another retreat by a big player in a highly competitive space after: $MRK terminates

EMA’s human medicines committee recommends 7 #medicines for approval at its December 2018 meeting https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018 … #CHMPpic.twitter.com/0oofJFa5Th

EMA’s human medicines committee recommends 7 #medicines for approval at its December 2018 meeting https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018 … #CHMP pic.twitter.com/0oofJFa5Th

Looking back, looking forward

14 December 2018 – What a great year 2018 has been for ADI! Amongst many highlights we have gained six new members, hosted four Alzheimer University training programmes, released four major reports, and seen the development of three new national dementia plans.  Innovation, especially innovation in care, is so important in...

The new Cancer Drugs Fund has quietly reached a significant milestone

Science blog This week, the National Institute for Health and Care Excellence (NICE) finished its review of a thyroid cancer drug called vandetanib (Caprelsa). This is business as usual for NICE, which decides whether the NHS should pay for new cancer medicines in England. NICE has completed 36 of these reviews for cancer drugs (or combinations of cancer drugs) this year alone. In this case, NI...

$ORTX and SIRION Biotech Announce Licensing Agreement to Enhance Gene Therapy Manufacturing Efficiency https://globenewswire.com/news-release/2018/12/14/1667236/0/en/Orchard-Therapeutics-and-SIRION-Biotech-Announce-Licensing-Agreement-to-Enhance-Gene-Ther

$ORTX and SIRION Biotech Announce Licensing Agreement to Enhance Gene Therapy Manufacturing Efficiency https://globenewswire.com/news-release/2018/12/14/1667236/0/en/Orchard-Therapeutics-and-SIRION-Biotech-Announce-Licensing-Agreement-to-Enhance-Gene-Therapy-Manufacturing-Efficiency.html …

$CPRX PT raised to $9 from $6 at HCW

$CPRX PT raised to $9 from $6 at HCW

$LPTX Presents TRX518 Data and Updated Data from DKN-01 Study in Biliary Tract Cancer #ESMOIO18 https://finance.yahoo.com/news/leap-therapeutics-presents-trx518-data-120000409.html …

$LPTX Presents TRX518 Data and Updated Data from DKN-01 Study in Biliary Tract Cancer #ESMOIO18 https://finance.yahoo.com/news/leap-therapeutics-presents-trx518-data-120000409.html …

Everybody is clamoring for Merck to spin off its animal health division so what do they do.....dig in. Nice. https://twitter.com/odibro/status/1073546177625448449 …

Everybody is clamoring for Merck to spin off its animal health division so what do they do.....dig in. Nice. https://twitter.com/odibro/status/1073546177625448449 …

$BLCM Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer #ESMOIO18 https://globenewswire.com/news-release/2018/12/14/1667210/0/en/Bellicum-Reports-Safety-Results-and-Promisin

$BLCM Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer #ESMOIO18 https://globenewswire.com/news-release/2018/12/14/1667210/0/en/Bellicum-Reports-Safety-Results-and-Promising-Activity-of-Its-Controlled-CAR-T-Candidate-BPX-601-in-Patie

$IDRA Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment https://globenewswire.com/news-release

$IDRA Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment https://globenewswire.com/news-release/2018/12/14/1667212/0/en/Idera-Pharmaceuticals-Presents-Clinical-Safety-and-Efficacy-Update-from-the-ILLUMINATE-204-Trial-of-the-Combina

$MRK to Acquire Privately Held Antelliq Group for €2.1B. Complements Merck Animal Health Portfolio of Vaccines and Pharmaceuticals https://www.businesswire.com/news/home/20181214005076/en/Merck-Acquire-Privately-Held-Antelliq-Group …

$MRK to Acquire Privately Held Antelliq Group for €2.1B. Complements Merck Animal Health Portfolio of Vaccines and Pharmaceuticals https://www.businesswire.com/news/home/20181214005076/en/Merck-Acquire-Privately-Held-Antelliq-Group …

Detailed results from AstraZeneca's MYSTIC study suggest survival benefit of Imfinzi, tremelimumab combination in patients with high TMB https://www.firstwordpharma.com/node/1611575  $AZN #ESMOImmuno18

Detailed results from AstraZeneca's MYSTIC study suggest survival benefit of Imfinzi, tremelimumab combination in patients with high TMB https://www.firstwordpharma.com/node/1611575  $AZN #ESMOImmuno18

Charts of the Year: Cash is king https://on.ft.com/2S10Lsk 

Charts of the Year: Cash is king https://on.ft.com/2S10Lsk 

Chatbots Supporting Mental Well-Being: Are We Playing A Dangerous Game?

Mental health is a complex multi-layered issue. Is the use of chatbots as mental health coaches ethical and moral?

WHO should finalize its BQ guidance

According to authors from the US, the World Health Organization (WHO) should finalize its Biological Qualifier (BQ) guidance. Distinguishable naming will allow quick and accurate tracing of the manufacturer of biologicals, should adverse events occur and improve patient safety by reducing confusion and mishaps. This will ensure that developing nations, including those in the Middle East and North ...

International promotion and education for biosimilars

International initiatives to promote the use of biosimilars and improve their understanding is just one of the subjects investigated by a report published by the Canadian Agency for Drugs and Technologies in Health (CADTH) [1].

British diabetologists issues position statement on biosimilar insulin

The Association of British Clinical Diabetologists (ABCD) has issued a position statement on the use of biosimilar insulin. The statement summarises information on the advantages and disadvantages of using biosimilar insulins and gives the association’s position on when biosimilar insulins be used [1].


Advertisement
Quick Search
Advertisement
Advertisement